FDA Inspection 1036696 — Amphastar Nanjing Pharmaceuticals Inc
The FDA completed an inspection of Amphastar Nanjing Pharmaceuticals Inc on October 26, 2017 in Nanjing. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- October 26, 2017
- Fiscal Year
- 2018
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Nanjing (China)